Application of peripheral CLU as target spot in reduction of brain A beta
The invention discloses application of peripheral CLU as a target spot in reduction of brain A beta. Specifically, the invention discloses application of peripheral CLU as a target spot in preparation of a product for preventing, improving or treating A beta related diseases. An RNAi-mediated gene knock-down method is taken as an example, and the effect of down-regulation of peripheral CLU on reduction of A beta load in the brain is elaborated. According to a mouse CLU gene sequence and an RNAi principle, by utilizing a short hairpin RNA sequence, the recombinant adeno-associated virus is cloned into an AAV8 adeno-associated virus expression vector, and the recombinant adeno-associated virus carrying knock-down shRNA (shRNA1) is obtained. Through intraperitoneal injection of recombinant adeno-associated virus into a transgenic mouse expressing human CLU (hCLU), it is verified that A beta in the brain can be remarkably reduced (the amount and deposition of beta-amyloid protein in the brain are inhibited) by reducing the expression or activity of the CLU gene in peripheral blood, and the excretion function of the CLU on the A beta in the brain can be played to the greatest extent..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 14. Apr. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WANG ZHE [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-04-14, Last update posted on www.tib.eu: 2023-09-26, Last updated: 2023-09-29 |
|---|
| Patentnummer: |
CN115957324 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA002002507 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA002002507 | ||
| 003 | DE-627 | ||
| 005 | 20240327214305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA002002507 | ||
| 035 | |a (EPA)CN115957324 | ||
| 035 | |a (EPA)87353209 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WANG ZHE |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of peripheral CLU as target spot in reduction of brain A beta |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-04-14, Last update posted on www.tib.eu: 2023-09-26, Last updated: 2023-09-29 | ||
| 520 | |a The invention discloses application of peripheral CLU as a target spot in reduction of brain A beta. Specifically, the invention discloses application of peripheral CLU as a target spot in preparation of a product for preventing, improving or treating A beta related diseases. An RNAi-mediated gene knock-down method is taken as an example, and the effect of down-regulation of peripheral CLU on reduction of A beta load in the brain is elaborated. According to a mouse CLU gene sequence and an RNAi principle, by utilizing a short hairpin RNA sequence, the recombinant adeno-associated virus is cloned into an AAV8 adeno-associated virus expression vector, and the recombinant adeno-associated virus carrying knock-down shRNA (shRNA1) is obtained. Through intraperitoneal injection of recombinant adeno-associated virus into a transgenic mouse expressing human CLU (hCLU), it is verified that A beta in the brain can be remarkably reduced (the amount and deposition of beta-amyloid protein in the brain are inhibited) by reducing the expression or activity of the CLU gene in peripheral blood, and the excretion function of the CLU on the A beta in the brain can be played to the greatest extent. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a WU YILI |4 aut | |
| 700 | 0 | |a LIANG WENPING |4 aut | |
| 700 | 0 | |a CHE RONGBO |4 aut | |
| 700 | 0 | |a LIU XI |4 aut | |
| 700 | 0 | |a LI YU |4 aut | |
| 700 | 0 | |a ZHANG YUN |4 aut | |
| 700 | 0 | |a SONG WEIHONG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 14. Apr. |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:04 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87353209/publication/CN115957324A1?q=CN115957324 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 04 | ||